throbber
Page 1
`
` A. ROSE
`UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
` _____________________________
`MICRO LABS LIMITED and MICRO LABS USA INC.
` Petitioners
` v.
` SANTEN PHARMACEUTICAL CO., LTD. and
` ASAHI GLASS CO., LTD.
` Patent Owners
` _____________________________
`
` Case IPR2017-01434
` U.S. Patent No. 5,886,035
` _____________________________
`
` DEPOSITION OF DR. ARON ROSE
` Washington, DC
` July 16, 2018
`
`Reported by: Mary Ann Payonk
`Job No. 143914
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`2
`3
`
`4 5
`
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR Page 1/123
`
`Santen/Asahi Glass Exhibit 2062
`Micro Labs v. Santen Pharm. and Asahi Glass
`IPR2017-01434
`
`

`

` A. ROSE
`
`Page 2
`
` July 16, 2018
` 9:03 a.m.
`
` Deposition of DR. ARON ROSE, held at the
`law offices of Pillsbury Winthrop Shaw Pittman
`LLP, 1200 Seventeenth Street, NW, Washington,
`DC, pursuant to Notice before Mary Ann
`Payonk, Nationally Certified Realtime Reporter
`and Notary Public of the District of Columbia,
`Commonwealth of Virginia, and State of New
`York.
`
`TSG Reporting - Worldwide 877-702-9580
`
`1
`
`2 3 4 5
`
`6
`
`7 8
`
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR Page 2/123
`
`

`

`Page 3
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`APPEARANCES:
`ON BEHALF OF PATENT OWNERS SANTEN
`PHARMACEUTICAL CO., LTD., and ASAHI GLASS CO.,
`LTD:
` ERNEST YAKOB, ESQUIRE
` HOGAN LOVELLS US
` 875 Third Avenue
` New York, New York 10022
`
`ON BEHALF OF PETITIONERS:
` CEDRIC TAN, ESQUIRE
` SOPHIE WEI, ESQUIRE
` ALTON HARE, ESQUIRE
` PILLSBURY WINTHROP SHAW PITTMAN
` 1200 Seventeenth Street, NW
` Washington, DC 20036
`
`ALSO PRESENT:
` Christopher Parker, Legal Video
` Specialist
` Ian Wahrenbrock, summer associate
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 3/123
`
`

`

`Page 4
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` THE VIDEOGRAPHER: This is the
`start of tape labeled number 1 of the
`videotaped deposition of Dr. Aron Rose
`in the matter of Micro Labs Limited and
`Micro Labs USA, Inc. versus Santen
`Pharmaceutical Company et al., in the
`United States Patent and Trademark
`Office before the Patent Trial and
`Appeal Board, case IPR2017-01434. This
`deposition is being held at 1200
`17th Street, Northwest, Washington, D.C.
`on July 16, 2018, at approximately 9:03.
` My name is Christopher Parker from
`TSG Reporting, Inc., and I'm the legal
`video specialist. The court reporter is
`Mary Ann Payonk, in association with
`TSG Reporting.
` Will counsel please introduce
`yourselves?
` (Whereupon, counsel placed their
`appearances on the video record.)
` MR. YAKOB: And just for the record
`there's also an additional person here.
`Do you want to state who that is for the
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 4/123
`
`

`

`Page 5
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` record?
` MR. TAN: Correct. We also have
` with us a summer associate with the
` Pillsbury law firm, and I'll let him
` introduce himself. His name is.
` MR. WAHRENBROCK: Ian Wahrenbrock.
`ARON ROSE,
` EXAMINATION
`BY MR. YAKOB:
` Q. Good morning, Dr. Rose.
` A. Good morning.
` Q. Some preliminary things to get
`started. Do you have any medical condition
`that would impair your ability to testify today
`truthfully and accurately?
` A. I do not.
` Q. And so the record goes smoothly and
`record appears smoothly, we can agree that
`you'll wait for me to ask my question and then
`you'll begin your answer; correct? So we don't
`overlap?
` A. Yes.
` Q. And so that the stenographer can
`capture the questions and the answers
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 5/123
`
`

`

`Page 6
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`correctly, we also agree that you will
`verbalize your answers rather than, for
`example, saying "uh-huh" or nodding?
` A. Yes.
` Q. Okay. Now, did you meet with counsel
`to prepare for your deposition today?
` A. I did.
` Q. Okay. And when was that?
` A. Yesterday, most recently.
` Q. Okay. And how long did you meet with
`counsel yesterday?
` A. Roughly eight hours.
` Q. Okay. Prior to yesterday's meeting,
`did you have any other preparation for this
`particular deposition?
` A. Yes.
` Q. Okay. And when was that?
` A. It was not in person. It was by
`telephone.
` Q. Okay. And approximately when was
`that?
` A. Scattered time periods since the last
`deposition.
` Q. Okay. And how long did you overall
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 6/123
`
`

`

`Page 7
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`meet with counsel to prepare for the deposition
`today?
` MR. TAN: Objection to form.
` A. Are you asking how many hours in
`total?
` Q. How many hours, yeah, in total.
` A. Including yesterday's time?
` Q. Including yesterday's time.
` A. I can only give you a rough estimate.
` Q. Okay.
` A. 20 hours.
` Q. Okay. And was any of that prior to
`you submitting your supplemental declaration in
`this matter?
` MR. TAN: Objection to form.
` A. I don't recall exactly.
` Q. I'll represent that you submitted
`your supplemental declaration -- or, excuse me,
`strike that.
` I'll submit that you signed your
`supplemental declaration on June 1, 2018.
` Do you agree with that?
` A. That's correct.
` Q. After June 1, 2018, how many hours
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 7/123
`
`

`

`Page 8
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`approximately did you spend preparing for this
`deposition?
` A. The great -- let me restate. The
`majority of the roughly 20 hours was spent
`after preparation of the supplemental
`declaration.
` Q. Okay. And the majority, do you mean
`more than 10 hours?
` MR. TAN: Objection to form.
` A. More than 50 percent.
` Q. Okay. Was it more than 15 hours that
`you spent preparing?
` A. I can't say with assurance.
` Q. And during your preparation with
`counsel for the deposition, did you review
`documents?
` MR. TAN: Objection to form.
` A. Yes, I did.
` Q. Okay. What documents did you review?
` MR. TAN: I'm going to make an
` objection; instruct the witness not to
` answer on the basis of privilege. What
` he may or may not have reviewed during
` his deposition preparation is protected
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 8/123
`
`

`

`Page 9
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` and privileged.
` MR. YAKOB: It's not a
` communication. I'm asking what
` documents did he review in preparation
` for his deposition. It's really not a
` proper instruction, counsel.
` MR. TAN: My objection stands. I
` am -- I stated my objection. It relates
` to documents that he may or may not have
` reviewed during his preparation. That
` is not a proper focus of your question
` and I'll instruct the witness not to
` answer.
` MR. YAKOB: I suggest you
` reconsider that over the break because
` it's really not a proper instruction.
` MR. TAN: My objection stands.
` MR. YAKOB: Okay.
`BY MR. YAKOB:
` Q. Did you communicate with anyone other
`than counsel to prepare for your deposition?
` A. I did not.
` Q. And you've prepared -- strike that.
` In terms of the drafting of your
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 9/123
`
`

`

`Page 10
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`declaration, your most recent declaration was a
`supplemental declaration that you signed on
`June 1, 2018; right?
` A. Correct.
` Q. You also previously submitted a
`declaration in this matter; correct?
` A. That's correct.
` Q. Do you understand when I refer to the
`supplemental declaration for purposes of our
`questioning I'll be referring to the one that
`you signed on June 1, 2018? Can we agree on
`that?
` A. I do.
` Q. Okay. When was the first draft of
`the supplemental declaration prepared?
` MR. TAN: Objection to form.
` A. I can't recall exactly.
` Q. Okay. And who prepared the first
`draft of the supplemental declaration?
` A. It was a collaboration between
`counsel and myself.
` Q. And did you review any other draft
`declarations while preparing your draft
`supplemental declaration?
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 10/123
`
`

`

`Page 11
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` MR. TAN: Objection to form.
` A. I'm not sure I understand your
`question.
` Q. Sure. Do you understand that
`Dr. deLong has also submitted a supplemental
`declaration in this proceeding?
` A. Yes.
` Q. Did you review any drafts of
`Dr. deLong's supplemental declaration while
`preparing your supplemental declaration?
` A. No, I did not.
` Q. Have you ever reviewed Dr. deLong's
`supplemental declaration?
` A. No.
` Q. Did you review Dr. deLong's original
`declaration in this proceeding?
` MR. TAN: Objection to form.
` A. I don't recall reviewing his original
`declaration.
` Q. And just to clarify for the record,
`I'm going to just -- so your supplemental
`declaration is Exhibit 1032, and Dr. deLong's
`supplemental declaration is Exhibit 1031, so
`that we're all clear here.
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 11/123
`
`

`

`Page 12
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` Do you know if Dr. deLong reviewed
`your supplemental declaration?
` MR. TAN: Objection to form.
` A. I have no information regarding this.
` Q. Okay.
` A. So I do have a distant recollection
`of reviewing Dr. deLong's original declaration.
` Q. And you reviewed that when?
` A. I can't recall.
` Q. Did you review Dr. deLong's original
`declaration in connection with the preparation
`of your supplemental declaration?
` A. I don't recall.
` Q. Do you recall anything in
`Dr. deLong's declaration that informed any of
`the opinions in either of your declarations?
` MR. TAN: Objection to form.
` A. Can you restate the question?
` Q. Sure. Why did you review
`Dr. deLong's original declaration?
` MR. TAN: Objection to form.
` A. As a member of a team constituting a
`person of ordinary skill in the art, it was
`important that I understood his area of
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 12/123
`
`

`

`Page 13
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`expertise. I recall now reviewing his original
`declaration, specifically because I was
`impressed by his depth of experience in the
`field.
` Q. Did you review his declaration to
`obtain any information for purposes of your own
`declarations?
` MR. TAN: Objection to form.
` A. Can you be more specific?
` Q. Did you rely on anything you read in
`Dr. deLong's declaration with respect to the
`opinions you rendered in your declaration?
` MR. TAN: Objection to form.
` A. As a comember of a team constituting
`a person of ordinary skill in the art, I looked
`to Dr. deLong's expertise as a medicinal
`chemist.
` Q. Okay. And the -- teams of
`individuals relying on each other's particular
`expertise is common in this field; correct?
` MR. TAN: Objection to form.
` A. I'm unable to answer that question.
` Q. That's the reason you reviewed -- you
`reviewed Dr. deLong's declaration because you
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 13/123
`
`

`

`Page 14
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`were relying on his expertise as a medicinal
`chemist; correct?
` MR. TAN: Objection to form.
` A. That's not exactly what I said. I
`did not use the phrase "relied on his
`expertise."
` Q. You looked to Dr. deLong's expertise
`as a medicinal chemist as a comember of a team
`constituting a person of ordinary skill in the
`art; correct?
` A. That's correct.
` MR. YAKOB: I'm going to hand you
` an exhibit that has been previously
` marked as Exhibit 2015 in this matter.
` (Exhibit No. 2015, previously marked, was
` referenced and indexed.)
`BY MR. YAKOB:
` Q. Dr. Rose, Exhibit 2015 is titled
`"Initial Clinical Studies with Prostaglandins
`and their Analogues."
` Do you see that?
` A. I do.
` Q. And this is at the top a February
`1997 paper by Camras and Albert Alm; is that
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 14/123
`
`

`

`Page 15
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`correct?
` A. That's correct.
` Q. Have you reviewed this paper before?
` MR. TAN: Objection to form.
` A. Yes.
` Q. The authors, as I mentioned, are
`Camras and Alm. Do you agree that both authors
`were at the forefront of the development of
`prostaglandin analogs as of December 26, 1996?
` MR. TAN: Objection to form.
` A. That's my understanding.
` Q. Let's look at the abstract of the
`paper. I'm going to direct your attention to I
`guess the fifth line down in the abstract on
`the first page. And it says: "Although
`PGF2alpha tromethamine salt,
`PGF2alpha-isopropyl ester," and then in
`parentheticals "(PGF2alpha-IE), and
`15-propionate-PGF2alpha-IE are all very
`effective in reducing IOP, they produce
`unacceptable side effects including
`conjunctival hyperemia and ocular irritation."
` Do you see that?
` A. I read that line, yes.
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 15/123
`
`

`

`Page 16
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` Q. So in February 1997, Camras and Alm
`are associating, for example, PGF2alpha and
`PGF2alpha-isopropyl ester with unacceptable
`side effects including conjunctival hyperemia;
`right?
` MR. TAN: Objection to form.
` A. PGF2alpha tromethamine salts,
`PGF2alpha-isopropyl esters and
`15-propionate-PGF2alpha-isopropyl ester are
`stated to produce unacceptable side effects
`including conjunctival hyperemia and ocular
`irritation.
` Q. Okay. And neither PGF2alpha nor
`PGF2alpha-isopropyl ester were ever
`commercialized as a glaucoma drug; is that
`correct?
` MR. TAN: Objection to form.
` A. Could you repeat the question?
` Q. Sure. Start with this.
`PGF2alpha-isopropyl ester has never been
`commercialized as a glaucoma medication;
`correct?
` A. Not to my knowledge.
` MR. YAKOB: Okay. You can set that
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 16/123
`
`

`

`Page 17
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`aside. I'm going to mark as a new
`exhibit, as Exhibit 2058, a journal
`article from the British Journal of
`Ophthalmology from 1994 titled "Additive
`Effect of Latanoprost, a Prostaglandin
`F2 Alpha Analog, and Timolol in Patients
`with Elevated Intraocular Pressure."
`The authors are Rulo, R-U-L-O, Greve,
`G-R-E-V-E, and Hoyng, H-O-Y-N-G.
`(Exhibit No. 2058 was marked for
`identification.)
` MR. TAN: I'm going to make an
`objection to this particular exhibit
`that you're going to question the
`witness on. It doesn't bear any
`markings indicating it was something
`that was filed with any of the papers
`with the PTAB. It is also outside the
`scope of the supplemental declaration as
`it does not look like it is a document
`that was part of his list of materials
`considered.
` MR. YAKOB: Can we have a standing
`objection to any newly marked exhibits?
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 17/123
`
`

`

`Page 18
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` MR. TAN: Sure.
` MR. YAKOB: Thanks.
` MR. TAN: And just to be clear,
` standing objection with respect to any
` exhibits that were not part of his list
` of materials considered and not part of
` any filing by either party with respect
` to the PTAB.
` MR. YAKOB: Okay.
`BY MR. YAKOB:
` Q. Dr. Rose, please take a moment to
`review that article and then I'm going to ask
`you if you've ever read this paper before.
` A. I've read the abstract.
` Q. Have you read this paper before?
` A. I don't recall.
` Q. Okay. And for the record, the title
`is "Additive Effect of Latanoprost, a
`Prostaglandin F2 Alpha Analog, and Timolol in
`Patients with Elevated Intraocular Pressure."
` Do you see that?
` A. Yes.
` Q. And this is in the British Journal of
`Ophthalmology from 1994; correct?
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 18/123
`
`

`

`Page 19
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` A. Yes.
` Q. And the first author is Rulo,
`R-U-L-O?
` A. Yes.
` Q. I'm going to ask you to take a look
`at the second page of the paper. This is page
`900 of the original article. In the right-hand
`column under the discussion, do you see the
`statement: "Previous studies using other
`prostaglandin analogs such as PGF2alpha-IE were
`hampered by clinically unacceptable grades of
`conjunctival hyperemia, local irritation, and
`pain sensation when optimal IOP-lowering doses
`were administered"?
` Do you see that?
` A. Yes.
` Q. So here again the authors are
`describing PGF2alpha-IE as hampered by
`clinically unacceptable hyperemia. Is that
`right?
` MR. TAN: Objection to form.
` A. That's what is written.
` Q. Okay. Now, please take a look at the
`references at the end of the article. First
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 19/123
`
`

`

`Page 20
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`direct your attention to the last page. This
`is page 4 of the article, also page 902 of the
`original numbering of the article.
` Do you see reference 18 as a
`reference to Kerstetter et al. with the title:
`"Prostaglandin F2 Alpha-1-isopropyl Ester
`Lowers Intraocular Pressure Without Decreasing
`Aqueous Humor Flow" in the American Journal of
`Ophthalmology, 1988?
` A. Yes.
` Q. So the authors were aware of the
`Kerstetter reference when they described
`PGF2alpha in their discussion; correct? Sorry,
`strike that.
` The authors were aware of Kerstetter
`in reference 18 when they described
`PGF2alpha-IE in their discussion; correct?
` MR. TAN: Objection to form.
` A. The authors cited the Kerstetter
`study, but I can't testify to their level of
`understanding of his work.
` Q. Okay.
` A. Nor the complexity of the issues
`raised in his paper.
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 20/123
`
`

`

`Page 21
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` Q. So let's look also at footnote --
`sorry. Strike that.
` Let's please look at reference 9 on
`page 3 of the article, also page 901 of the
`original numbering of the article.
` Do you see that reference 9 is
`Villumsen, Alm: "Prostaglandin F2
`Alpha-Isopropyl Ester Eye Drops: Effects in
`Normal Human Eyes" in the British Journal of
`Ophthalmology, 1989?
` A. Yes.
` Q. You can set that aside. I'm going to
`hand you what's been previously marked as
`Exhibit 1033, and it is an article entitled
`"Prostaglandin F2 Alpha-1-Isopropyl Ester
`Lowers Intraocular Pressure Without Decreasing
`Aqueous Humor Flow" by Kerstetter, et al.
` (Micro Labs Exhibit No. 1033, previously
` marked, was referenced and indexed.)
`BY MR. YAKOB:
` Q. Dr. Rose, do you recognize this
`paper?
` A. I do.
` MR. TAN: Objection to form.
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 21/123
`
`

`

`Page 22
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` Q. Have you reviewed Exhibit 1033 in its
`entirety?
` MR. TAN: Objection to form.
` A. I believe I have.
` Q. Okay. And again, you see the title
`is "Prostaglandin F2 Alpha-1-Isopropyl Ester
`Lowers Intraocular Pressure Without Decreasing
`Aqueous Humor Flow"; correct?
` A. Yes.
` Q. The first author is Kerstetter,
`K-E-R-S-T-E-T-T-E-R?
` A. Yes.
` Q. I'll initially direct your attention
`to the abstract and the description of the
`study that was being done. In the first
`sentence it says: "Using fluorophotometry, we
`performed a randomized, dose-response study of
`the effects of a prostaglandin derivative on
`aqueous humor flow."
` Do you see that?
` A. Yes.
` Q. So the patients here were receiving
`increasing doses of the PGF2alpha-isopropyl
`ester; correct?
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 22/123
`
`

`

`Page 23
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` MR. TAN: Objection to form.
` A. Yes.
` Q. And let's just read the next
`sentence. "Prostaglandin F2 alpha-1-isopropyl
`ester, 0.224 micrograms, 0.448 micrograms, and
`1.120 micrograms, in saline with polysorbate 80
`was instilled into one eye of 20 subjects in
`three separate dose studies." In total in this
`study there were 20 subjects; correct?
` A. That's what the abstract says.
` Q. Okay. Maybe we can confirm that in a
`second as well. Let's look at page 3. And
`this is page 32 of the original numbering of
`the article. And I'm going to direct your
`attention to the Results section. It says:
`"All 20 subjects completed the study of the 1
`and 2-microliter doses."
` Do you see that?
` A. I do.
` Q. Okay. So again, there were 20
`subjects in the study; correct?
` A. Yes.
` Q. Okay. The next sentence says:
`"However, two subjects complained of pain and
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 23/123
`
`

`

`Page 24
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`photophobia and were noted to have marked
`conjunctival hyperemia for several hours after
`instillation of the 2-microliter dose. They
`were excluded from tests of the 5-microliter
`dose."
` Do you see that?
` A. Yes.
` Q. So the authors are describing that
`two of 20 patients could not complete the study
`for all doses because of marked conjunctival
`hyperemia; correct?
` MR. TAN: Objection to form.
` A. At concentrations of 2 microliters.
` Q. Just to clarify, but the study is
`saying that two of the 20 patients could not
`complete the study for all doses because of
`marked conjunctival hyperemia; right?
` A. That's correct.
` Q. And two of 20 patients, that's
`10 percent of the patients in the study; right?
` MR. TAN: Objection to form.
` A. Yes.
` MR. YAKOB: Okay. You can set that
` aside. Dr. Rose, I'm going to hand you
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 24/123
`
`

`

`Page 25
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` what's been previously marked in this
` proceeding Exhibit 1003. It's a
` European patent application with Peter
` Klimko as the first inventor and the
` publication number is 639563.
` (Micro Labs Exhibit No. 1003, previously
` marked, was referenced and indexed.)
`BY MR. YAKOB:
` Q. Dr. Rose, do you recognize
`Exhibit 1003?
` A. I do.
` Q. Okay. Can we agree to refer to
`Exhibit 1003 as Klimko?
` A. Yes.
` Q. I'm going to direct your attention to
`table 4 on page 18 of Klimko. You're familiar
`with table 4 on page 18 of Exhibit 1003;
`correct?
` A. I am.
` Q. Okay. Klimko doesn't provide any
`percent IOP reduction data for a time point
`later than 16 hours after a dose; is that
`right?
` MR. TAN: Objection to form.
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 25/123
`
`

`

`Page 26
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` A. Did you say after a dose?
` Q. After a dose.
` A. And can you repeat the question?
` Q. Sure. So Klimko, Exhibit 1003,
`doesn't provide any percent IOP reduction data
`for a time point later than 16 hours after a
`dose.
` A. Correct.
` Q. For example, there's no measurement
`of a 24-hour time point after a dose; right?
` MR. TAN: Objection to form.
` A. I find your use of the words "a dose"
`to be confusing. Can you be more precise?
` Q. There's no measurement of a 24-hour
`time point after a dose and before another
`dose; correct?
` MR. TAN: Objection to form.
` A. My reading of Klimko is aided by the
`description of the protocol used for this study
`or quoted in this study. That has to do with
`the administration of successive doses at
`specific time periods, and therefore, the use
`of the word "a dose" continues to confuse me.
` Q. There -- all the doses in Klimko were
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 26/123
`
`

`

`Page 27
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`given at time points less than 24 hours apart;
`is that correct?
` MR. TAN: Objection to form.
` A. Apart from each other?
` Q. Yes. So just to rephrase the
`question.
` A. Yes, thank you.
` Q. It was more like restating the
`question, just for clarity of the record. All
`of the doses that were administered for
`purposes of table 4 in Exhibit 1003 were
`administered at less than 24 hours apart from
`each other; correct?
` MR. TAN: Objection to form.
` A. I believe the time points were 0, 8
`hours, 16 hours, 24 hours, and 32 hours, to be
`precise.
` Q. And 48 hours; correct?
` A. The next was at 48 hours.
` Q. And so I'll reask the question again.
`So all the doses that were administered for
`purposes of table 4 in Exhibit 1003 were
`administered at less than 24 hours apart from
`each other.
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 27/123
`
`

`

`Page 28
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` MR. TAN: Objection to form.
` A. Less than 24-hour intervals would be
`another way of stating that?
` Q. I'll restate it your way. All the
`doses that were administered for purposes of
`table 4 in Exhibit 1003 were administered at
`intervals of less than 24 hours apart from each
`other; correct?
` A. Yes.
` Q. Therefore, there was no time point --
`strike that.
` Therefore, there is no data in table
`4 of Klimko Exhibit 1003 for a time point at 24
`hours after administration of a particular dose
`and before the administration of a following
`dose?
` MR. TAN: Objection to form.
` A. I'm sorry, I'm very confused.
` Q. Yeah. There's no time point -- given
`the administration schedule in Klimko for
`purposes of table 4, there's no time point for
`24 hours after one dose and before the
`following dose; correct?
` MR. TAN: Same objection.
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 28/123
`
`

`

`Page 29
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` A. So that I understand, is this a
`restatement of the same question in a different
`form?
` Q. It's a corollary. Given the
`administration schedule that we just discussed,
`correct, where there was no dose that was given
`at an interval of 24 hours apart, there's no
`data point in Klimko for a time point that's 24
`hours after a particular dose yet before the
`following dose.
` MR. TAN: Objection to the form.
` Q. Correct?
` A. The doses were given at hour 8, 16,
`24, 32, and 48. I find it's unconfusing to
`restate that fact. I'm somewhat confused by
`your question.
` Q. The doses that were described in
`Klimko, Exhibit 1003, were 16 hours after the
`fourth dose, 2 hours after the fifth dose, 4
`hours after the fifth dose, and 6 hours after
`the fifth dose; correct?
` A. Correct.
` Q. There were no other percent IOP
`reduction data presented for any other time
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 29/123
`
`

`

`Page 30
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`points other than 16 hours after the fourth
`dose, 2 hours after the fifth dose, 4 hours
`after the fifth dose, and 6 hours after the
`fifth dose; correct?
` A. Correct.
` MR. TAN: Objection to form.
` Q. Now, is it your position that none of
`Compounds A, B, and D in table 4 would provide
`IOP lowering at 24 hours after a single dose?
` MR. TAN: Objection to form.
` A. Can you restate the question?
` Q. Sure. Is it your position -- I can
`say it again, but you let me know --
` A. Uh-huh.
` Q. Is it your position that none of
`Compounds A, B, and D would provide IOP
`lowering 24 hours after the administration of a
`dose?
` MR. TAN: Same objection.
` A. I'm sorry. I remain confused by your
`question. Could you kindly restate it?
` Q. Table 4, the last measured time
`point -- last measured time point in table 4 is
`6 hours after the fifth dose; correct?
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 30/123
`
`

`

`Page 31
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` A. Correct.
` Q. Okay. Is it your position -- strike
`that.
` Is it your position that if the
`percent IOP reduction were measured at 24 hours
`after the fifth dose, there would be no IOP
`lowering for Compounds A, B, and D?
` MR. TAN: Objection to form.
` A. The data suggests that.
` Q. That it would be zero?
` A. I can't predict that.
` Q. So you can't predict what the IOP
`would be at 24 hours after the fifth dose for
`Compounds A, B and D; correct?
` MR. TAN: Objection to form.
` A. The data strongly suggests the
`likelihood, but I cannot give a prediction.
` Q. I'm sorry. You -- I'll reask the
`question again. You can't predict the specific
`percent IOP reduction for Compounds A, B and D
`at 24 hours after the fifth dose; is that
`right?
` MR. TAN: Objection to form.
` A. The data suggests a strong
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 31/123
`
`

`

`Page 32
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
`likelihood, but that is different than a
`prediction.
` Q. Just to clarify, you're saying that
`there is a strong likelihood that the IOP
`reduction would be diminished; is that right?
` A. Can you restate that in a more
`complete form?
` Q. I guess -- you keep saying the
`likelihood is strong.
` A. Yes.
` Q. I'm trying to clarify what you're
`referring to.
` A. Uh-huh.
` Q. My question is not about -- my
`question is a stand-alone question. At 24
`hours after the fifth dose, you can't predict
`what the -- what specific percent IOP reduction
`is for Compounds A, B and D; correct?
` MR. TAN: Objection to form.
` A. I cannot predict the exact IOP at 24
`hours after the fifth dose.
` Q. Okay. Now, let's move to the next
`paper.
` MR. YAKOB: I'm going to ask the
`
`TSG Reporting - Worldwide 877-702-9580
`
`IPR Page 32/123
`
`

`

`Page 33
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
` A. ROSE
` reporter to mark as Exhibit 2059 a paper
` by Villumsen and Alm in the British
` Journal of Ophthalmology, 1992, titled
` "PhXA34 -- A Prostaglandin F2 Alpha
` Analog. Effect on Intraocular Pressure
` in Patients with Ocular Hypertension."
` (Exhibit No. 2059 was marked for
` identification.)
` MR. TAN: My standing objection
` stands here, counsel, just to confirm?
` MR. YAKOB: Yeah.
`BY MR. YAKOB:
` Q. Dr. Rose, please review Exhibit 2059

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket